Comparative Pharmacology
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL versus NATURAL ESTROGENIC SUBSTANCE ESTRONE.
ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL vs NATURAL ESTROGENIC SUBSTANCE-ESTRONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethynodiol diacetate is a progestin that suppresses gonadotropin secretion (LH and FSH) via negative feedback on the hypothalamic-pituitary axis, inhibiting ovulation; ethinyl estradiol is an estrogen that stabilizes the endometrium and increases cervical mucus viscosity, impeding sperm penetration.
Estrone binds to and activates estrogen receptors (ERα and ERβ), leading to modulation of gene transcription and subsequent estrogenic effects on target tissues.
1 tablet (1 mg ethynodiol diacetate / 35 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo days.
0.1 to 0.5 mg intramuscularly 2 to 3 times per week for estrogen replacement therapy
None Documented
None Documented
Ethynodiol diacetate: 12-14 hours; ethinyl estradiol: 13-27 hours (mean ~17 hours). Steady-state achieved after 3-4 days.
Terminal half-life: 24-48 hours (prolonged due to enterohepatic recirculation and tissue distribution).
Renal (approximately 40% as metabolites), fecal (approximately 60% as metabolites). Ethynodiol diacetate is extensively metabolized; less than 1% excreted unchanged.
Renal: ~50% (as glucuronide and sulfate conjugates), Biliary/Fecal: ~50% (enterohepatic recirculation).
Category D/X
Category C
Estrogen
Estrogen